STOCK TITAN

Alpha Tau Medical’s 9-month net loss rises to $98.9M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. (DRTS) reported third-quarter 2026 financial results and clinical updates. Net loss for the nine months ended September 30, 2026 was $98.9 million, compared with $30.5 million in the same period of 2025. Research and development expense was $31.7 million versus $22.5 million; financial expenses, net, were $58.5 million versus $0.6 million. Cash, cash equivalents, short-term deposits and restricted deposits totaled $99.8 million as of September 30, 2026, compared with $76.9 million at December 31, 2025.

In interim REGAIN results for recurrent glioblastoma, all eight treated patients were alive and median overall survival had not been reached. The first six evaluable patients had a 100% objective response rate, including five complete responses, at 6.9 months’ median follow-up. The FDA approved expanding the trial from 10 to up to 20 patients; Alpha Tau believes the data could support market submission requirements. IMPACT enrollment was completed with 48 patients across 10 clinical centers. The first stage of the Hudson plant is targeted to be ready for clinical-trial supply by the end of 2026.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNine-month net loss increased to $98.9 million from $30.5 million in the same period of 2025.

Filing Explained

At September 30, 2026, Alpha Tau reported 93,084,841 ordinary shares issued and outstanding, versus 88,009,737 at December 31, 2025; holders whose share counts did not rise proportionately therefore held a smaller fraction of the company.

Net loss $98.9 million Nine months ended September 30, 2026; $30.5 million in the same period of 2025.
Research and development expenses $31.7 million Nine months ended September 30, 2026; $22.5 million in the same period of 2025.
Financial expenses, net $58.5 million Nine months ended September 30, 2026; $0.6 million in the same period of 2025.
Cash, cash equivalents, short-term deposits and restricted deposits $99.8 million As of September 30, 2026; $76.9 million as of December 31, 2025.
REGAIN treated patients alive 8 patients Interim results in recurrent glioblastoma; median overall survival not reached.
Objective response rate 100% First six evaluable REGAIN patients; 6.9 months’ median follow-up.
Complete responses 5 responses Among the first six evaluable REGAIN patients.
IMPACT pilot enrollment 48 patients Across 10 clinical centers in the U.S., Canada and Israel.
median overall survival medical
"median overall survival not reached"
Median overall survival is the middle point of how long patients live after starting treatment, meaning half live longer and half live shorter. It helps doctors understand how effective a treatment is and gives patients an idea of what to expect about their future.
objective response rate medical
"100% objective response rate"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
radium-224 impregnated sources technical
"intratumoral delivery of radium-224 impregnated sources"
warrants liability financial
"remeasurement of warrants liability"
Warrants liability is an accounting label for warrants when they are treated as a company obligation rather than equity. Think of a warrant like a coupon that might force the company to hand over cash or change the amount of stock depending on future events; when those outcomes aren’t fixed, accountants put it on the liabilities side of the balance sheet. For investors this matters because it can increase a company’s reported debt, affect future cash needs, and change potential share dilution and valuation.
short-lived daughters medical
"its short-lived daughters are released from the sources"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Alpha Tau’s interim REGAIN results?

Alpha Tau reported that all eight treated patients were alive, with median overall survival not reached. Among the first six evaluable patients, the objective response rate was 100%, including five complete responses, at 6.9 months’ median follow-up.

What was Alpha Tau’s net loss for the first nine months of 2026?

Alpha Tau reported a net loss of $98.9 million for the nine months ended September 30, 2026, compared with $30.5 million for the same period in 2025. Net loss per share was $1.09, versus $0.39.

Why were Alpha Tau’s financial expenses higher in 2026?

Financial expenses, net, were $58.5 million for the nine months ended September 30, 2026, compared with $0.6 million in 2025. Alpha Tau attributed the increase primarily to remeasurement of warrant liability as trading prices of its ordinary shares and publicly traded warrants rose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-41316

 

 

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

 

CONTENTS

 

On November 19, 2026, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

This Report and the related exhibits, other than the quote included in Exhibit 99.1, are incorporated by reference into the registrant's Registration Statements on Form F-3 (File Nos. 333-264306, 333-274457, 333-288240 and 333-295359) and Form S-8 (File Nos. 333-264169, 333-270406, 333-277733, 333-285745 and 333-294151).

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release dated November 19, 2026.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Alpha Tau Medical Ltd.
     
Date: November 19, 2026 By: /s/ Uzi Sofer
    Uzi Sofer
    Chief Executive Officer

 

3

 

Exhibit 99.1

 

Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update

 

- New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall survival not reached, and a 100% objective response rate, including five complete responses, in the first six evaluable patients at 6.9 months median follow-up, with 100% feasibility and no unanticipated serious adverse events -

 

- FDA approval to expand the REGAIN trial from 10 to up to 20 patients, which the Company believes could generate data that may support market submission requirements for Alpha DaRT® in recurrent glioblastoma -

 

- Completion of patient enrollment in the multicenter IMPACT pancreatic cancer pilot study, with 48 patients enrolled across 10 clinical centers in the U.S., Canada and Israel following strong demand and three trial expansions -

 

- Dual listing on the Tel Aviv Stock Exchange (TASE), followed by inclusion in the flagship TA-90 and TA-125 indices -

 

- Meaningful additional data anticipated from multiple trials in the coming months -

 

- Ongoing manufacturing scale-up, with the first stage of the Company’s Hudson, New Hampshire plant targeted to be ready for clinical trial supply by the end of 2026 -

 

- Cash, cash equivalents, short-term deposits and restricted deposits balance of $99.8 million provides runway for continued clinical advancement and commercial preparation -

 

JERUSALEM, November 19, 2026 - Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ / TASE: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported third quarter 2026 financial results and provided a corporate update.

 

“Alpha Tau has tremendous momentum right now, and the new fantastic interim data from our REGAIN trial in recurrent glioblastoma showcase the true power of Alpha DaRT,” said Alpha Tau CEO Uzi Sofer. “While the trial started with a focus on feasibility and safety, we initially begin to see responses to the treatment, and are now seeing this translate into patient survival. We will continue to follow these patients closely as their scans mature, but we believe they speak to what a potent, highly localized alpha-emitting therapy may be able to do in even the hardest-to-treat tumors. With the FDA having approved the expansion of REGAIN to up to 20 patients, which we believe may support market submission requirements for Alpha DaRT, we are pressing ahead with enrollment, while preparing for mass production and commercialization if and when we are able to secure such an authorization.”

 

“The glioblastoma data reflect only one part of Alpha Tau’s much broader opportunity to meaningfully change how cancer is treated,” continued Mr. Sofer. “In recent months we completed enrollment of 48 patients in our multicenter IMPACT pancreatic cancer pilot study, after three expansions driven by strong demand, and treated the first immunocompromised patient in our ADMIRE study. We now expect meaningful additional data from multiple trials in the coming months, including top-line data from our pivotal ReSTART trial in recurrent cSCC, initial data from IMPACT, and additional interim data from REGAIN.”

 

 

 

 

“To be ready for the demand that we believe these data can generate, we continue to scale up our manufacturing capabilities. A central piece of that effort is bringing the first stage of our Hudson, New Hampshire plant online, which we are targeting to be ready for clinical trial supply by the end of 2026.”

 

“On the corporate front, we are very pleased to have come home to Israel with our dual listing on the Tel Aviv Stock Exchange, quickly followed by our inclusion in the flagship TA-90 and TA-125 indices. With a strong balance sheet of $99.8 million, a growing body of clinical evidence across multiple tumor types, and a dense calendar of data readouts ahead of us, we believe Alpha Tau has never been better positioned to translate this momentum into meaningful impact for patients.”

 

Recent Corporate Highlights:

 

●In November 2026, Alpha Tau announced new interim results from its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT in recurrent glioblastoma (GBM), presented at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia by the study investigator team from The Ohio State University Comprehensive Cancer Center. As of the November 11, 2026 data cut-off, all eight patients treated in the trial were alive and median overall survival had not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who had reached response assessment. All six of these patients (100%) achieved an objective response as their best overall response under RANO criteria, comprising five complete responses (83.3%) and one partial response (16.7%) with a 58% decrease in tumor measurements. On the trial’s primary endpoints of feasibility and safety, all planned Alpha DaRT sources were successfully deployed in all eight patients (100%), with no unanticipated serious adverse events. No definitive recurrence within the treated area has been reported in any patient, although one patient developed tumor progression away from the treated area approximately nine months after treatment. The results follow the FDA’s approval in October 2026 of an Investigational Device Exemption (IDE) supplement expanding REGAIN from 10 to up to 20 patients across three U.S. academic cancer centers and adding progression-free survival as a secondary endpoint, regular quality-of-life assessments and an additional interim analysis. The Company believes that the expanded trial could generate data that may support market submission requirements for Alpha DaRT in recurrent GBM. For more information, please see here: https://www.clinicaltrials.gov/study/NCT06910306

 

●In October 2026, Alpha Tau announced the inclusion of its ordinary shares in the flagship TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE), effective November 5, 2026, making Alpha Tau one of three biomed companies in the TA-125, with funds tracking these indices expected to add Alpha Tau shares to their holdings. The index inclusion follows the Company’s dual listing on the TASE in August 2026, which was undertaken in light of growing interest from Israeli investors and requests from the local investor base to trade the Company’s shares in local currency and during local business hours. The Company’s ordinary shares now trade on both Nasdaq and the TASE under the symbol DRTS.

 

●In August 2026, Alpha Tau announced the completion of patient enrollment in its multicenter IMPACT (Intratumoral Pancreatic Alpha Combination Trial) pilot study of Alpha DaRT in pancreatic cancer, with 48 patients enrolled across 10 clinical centers in the United States, Canada and Israel. Originally approved for 12 patients, the study was expanded three times following strong demand, with the third expansion requested by participating clinical sites and broadening eligibility to multiple disease stages and both first-line chemotherapy regimens. IMPACT evaluates a one-time intratumoral Alpha DaRT treatment, delivered under real-time endoscopic ultrasound (EUS) guidance, as an add-on to first-line chemotherapy with either mFOLFIRINOX or gemcitabine with Abraxane® (nab-paclitaxel), in patients with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. For more information, please see here: https://www.clinicaltrials.gov/study/NCT06698458

 

2

 

 

●In July 2026, Alpha Tau reported positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), delivered in a podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer in Boston. Among all nine evaluable patients, the combination produced a systemic objective response rate of 100%, including four complete responses and five partial responses, compared to just 19% from historical benchmarks for pembrolizumab monotherapy in this setting. Median overall survival of 18.2 months and median progression-free survival of 5.4 months compared favorably with historical benchmarks for pembrolizumab monotherapy of 12.3 months and 3.2 months, respectively. No Alpha DaRT-associated serious adverse events were observed, and the study was stopped after the recruitment of 11 patients, having surpassed its pre-specified threshold for success.

 

●In July 2026, Alpha Tau announced the successful treatment of the first patient in its ADMIRE (Alpha DaRT Management for Immunocompromised patients with REcurrent cSCC) study, a clinical trial evaluating intratumoral Alpha DaRT in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC), performed at Banner MD Anderson Cancer Center in Gilbert, Arizona. Immunosuppression is one of the strongest known risk factors for cSCC, and these patients are frequently excluded from clinical trials and often cannot safely receive checkpoint inhibitor immunotherapy. The prospective, multicenter, open-label, single-arm study is designed to enroll up to 28 patients at up to eight U.S. sites. For more information, please see here: https://clinicaltrials.gov/study/NCT06615635

 

Expected Upcoming Milestone Targets:

 

●First patient treated in U.S. locally recurrent prostate cancer pilot trial at year end 2026. For more information, please see here: https://clinicaltrials.gov/study/NCT07290998

 

●Top-line data in the ReSTART pivotal U.S. multi-center trial in recurrent cSCC in Q1 2027, followed by a potential submission to the FDA. For more information, please see here: https://www.clinicaltrials.gov/study/NCT05323253

 

●Additional interim data from the REGAIN recurrent GBM trial in the U.S. in Q1 2027. For more information, please see here: https://www.clinicaltrials.gov/study/NCT06910306

 

●Initial data from the IMPACT pancreatic cancer pilot study in H1 2027. For more information, please see here: https://www.clinicaltrials.gov/study/NCT06698458

 

3

 

 

Financial Results for the Nine Months Ended September 30, 2026

 

Research and Development expenses for the nine months ended September 30, 2026 were $31.7 million, compared to $22.5 million for the same period in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, increased clinical trial activity and payments to subcontractors, and increased raw material purchases.

 

Marketing expenses for the nine months ended September 30, 2026 were $0.9 million, compared to $1.4 million for the same period in 2025, primarily due to decreased employee compensation and benefits.

 

General and Administrative expenses for the nine months ended September 30, 2026 were $7.6 million, compared to $5.8 million for the same period in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, and higher professional fees.

 

Financial expenses, net, for the nine months ended September 30, 2026 were $58.5 million, compared to $0.6 million for the same period in 2025, primarily due to the remeasurement of warrants liability, as the public trading prices of the Company’s ordinary shares and publicly traded warrants rose over the period.

 

For the nine months ended September 30, 2026, the Company had a net loss of $98.9 million, or $1.09 per share, compared to a net loss of $30.5 million, or $0.39 per share, for the nine months ended September 30, 2025.

 

Balance Sheet Highlights

 

As of September 30, 2026, the Company had cash and cash equivalents, short-term deposits and restricted deposits of $99.8 million, compared to $76.9 million at December 31, 2025.

 

About Alpha DaRT

 

Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

 

About Alpha Tau Medical Ltd.

 

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

 

4

 

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “believe,” “expect,” “will,” “plan,” “may,” “could,” “continue,” “aim,” “goal,” “target,” “potential,” “designed to,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, milestone targets, beliefs, plans, including with respect to clinical trials and planned treatments regulatory approvals and expected responses, studies, patient recruitment, the anticipated timing of data readouts, projections, objectives, performance, our ability to commercialize, our manufacturing facilities and future production, including the timing of readiness of the Hudson, New Hampshire plant, the Company’s financial position and cash runway, the anticipated effects of the Company’s TASE listing and index inclusion, applications with regulatory bodies or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on Form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

 

Investor Relations Contact:

 

IR@alphatau.com

 

5

 

 

INTERIM CONSOLIDATED BALANCE SHEETS

 

U.S. dollars in thousands

 

   December 31,   September 30, 
   2025   2026 
       Unaudited 
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents  $12,202   $17,025 
Short-term deposits   60,924    78,699 
Restricted deposits   3,777    4,070 
Prepaid expenses and other receivables   1,395    1,781 
           
Total current assets   78,298    101,575 
           
LONG-TERM ASSETS:          
Long-term prepaid expenses   479    523 
Property and equipment, net   19,661    19,191 
Operating lease right-of-use assets   7,214    7,667 
           
Total long-term assets   27,354    27,381 
           
Total assets  $105,652   $128,956 

 

6

 

 

INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

 

   December 31,   September 30, 
   2025   2026 
       Unaudited 
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
         
CURRENT LIABILITIES:        
Trade payables  $3,868   $3,680 
Other payables and accrued expenses   5,508    5,726 
Current maturities of operating lease liabilities   1,131    1,327 
           
Total current liabilities   10,507    10,733 
           
LONG-TERM LIABILITIES:          
Long-term loan   6,352    6,615 
Warrants liability   5,354    66,035 
Operating lease liabilities   6,243    6,738 
Deferred revenue   -    18,878 
Deferred tax liability   97    310 
           
Total long-term liabilities   18,046    98,576 
           
Total liabilities   28,553    109,309 
           
SHAREHOLDERS’ EQUITY:          
Ordinary shares of no-par value per share – Authorized: 362,116,800 shares as of December 31, 2025 and September 30, 2026; Issued and outstanding: 88,009,737 and 93,084,841 shares as of December 31, 2025 and September 30, 2026 respectively   -    - 
Additional paid-in capital   267,235    308,689 
Accumulated deficit   (190,136)   (289,042)
           
Total shareholders’ equity   77,099    19,647 
           
Total liabilities and shareholders’ equity  $105,652   $128,956 

 

7

 

 

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and per share data)

 

   Nine months ended
September 30,
 
   2025   2026 
   Unaudited 
         
Research and development  $22,489   $31,686 
           
Marketing expenses   1,408    920 
           
General and administrative   5,789    7,623 
           
Total operating loss   29,686    40,229 
           
Financial expenses, net   649    58,461 
           
Loss before taxes on income   30,335    98,690 
           
Tax on income   156    216 
           
Net loss   30,491    98,906 
           
Net loss per share, basic and diluted  $0.39   $1.09 
           
Weighted-average shares used in computing net loss per share, basic and diluted   78,721,389    91,103,211 

 

8

 

Filing Exhibits & Attachments

1 document

Keep reading